Cargando…
Elevated TNFRSF4 gene expression is a predictor of poor prognosis in non-M3 acute myeloid leukemia
BACKGROUND: We used bioinformatic tools to dichotomize 157 non-M3 AML patients from the TCGA dataset based on the presence or absence of TP53 mutations, and screened out a key gene related to TP53 mutation for future analysis. METHODS: DEGs were analyzed by R package “DESeq2” and then run GSEA, GO e...
Autores principales: | Gu, Siyu, Zi, Jie, Han, Qi, Song, Chunhua, Ge, Zheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197135/ https://www.ncbi.nlm.nih.gov/pubmed/32390761 http://dx.doi.org/10.1186/s12935-020-01213-y |
Ejemplares similares
-
Clinical and laboratory features of seven patients with acute myeloid leukemia (AML)-M2/M3 and elevated myeloblasts and abnormal promyelocytes
por: He, GanLin, et al.
Publicado: (2014) -
The prognosis biomarkers based on m6A-related lncRNAs for myeloid leukemia patients
por: Yang, Li-Rong, et al.
Publicado: (2022) -
CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2020) -
TNFRSF13B is a potential contributor to prostate cancer
por: Li, Chia-Yang, et al.
Publicado: (2022) -
Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms
por: Zhang, Qi, et al.
Publicado: (2019)